CNST Key Statistics, Chart & Performance
The current stock price of CNST is 33.99 null. In the past month the price increased by 0.77%. In the past year, price increased by 16.8%.
CNST Latest News, Press Relases and Analysis
CNST Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.6 | 394.11B | ||
| AMGN | AMGEN INC | 14.35 | 169.00B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 148.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.17 | 110.88B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.39 | 72.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 814.14 | 54.85B | ||
| INSM | INSMED INC | N/A | 41.41B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.5 | 25.80B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.05 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B | ||
| INCY | INCYTE CORP | 14.82 | 18.68B |
Related stock screener links
About CNST
Company Profile
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company is headquartered in Cambridge, Massachusetts and currently employs 154 full-time employees. The company went IPO on 2018-07-19. The firm has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The firm is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.
Company Info
Constellation Pharmaceuticals Inc
215 1st St Ste 200
Cambridge MASSACHUSETTS 02142 US
CEO: Jigar Raythatha
Employees: 154.0
Phone: 16177140555.0
Constellation Pharmaceuticals Inc / CNST FAQ
What does CNST do?
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company is headquartered in Cambridge, Massachusetts and currently employs 154 full-time employees. The company went IPO on 2018-07-19. The firm has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The firm is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.
What is the stock price of Constellation Pharmaceuticals Inc today?
The current stock price of CNST is 33.99 null. The price increased by 0.06% in the last trading session.
Does CNST stock pay dividends?
CNST does not pay a dividend.
How is the ChartMill rating for Constellation Pharmaceuticals Inc?
CNST has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does Constellation Pharmaceuticals Inc have?
Constellation Pharmaceuticals Inc (CNST) currently has 154.0 employees.
CNST Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CNST. When comparing the yearly performance of all stocks, CNST is one of the better performing stocks in the market, outperforming 78.24% of all stocks.
CNST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNST. No worries on liquidiy or solvency for CNST as it has an excellent financial health rating, but there are worries on the profitability.
CNST Financial Highlights
Over the last trailing twelve months CNST reported a non-GAAP Earnings per Share(EPS) of -3.04. The EPS decreased by -4.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.01% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CNST Forecast & Estimates
7 analysts have analysed CNST and the average price target is 41.53 null. This implies a price increase of 22.18% is expected in the next year compared to the current price of 33.99.